Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study

The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses, has been proposed to enhance the immune resp...

Full description

Bibliographic Details
Main Authors: Kriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, Fahsiri Tavonvunchai, Anchisa Lievjaroen, Paphada Suwannaroj, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Gaidganok Sornsamdang, Teerapat Ungtrakul
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
covid-19
heterologous prime-boost
vaccine combination
chadox1 ncov-19
azd1222
coronavac
bbibp-corv
Online Access:http://dx.doi.org/10.1080/21645515.2023.2206360

Internet

http://dx.doi.org/10.1080/21645515.2023.2206360

Similar Items